Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

08 Jan 2026, 02:52 by Scott Moore · The Cerbat Gem

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw some unusual options trading on Wednesday. Investors acquired 4,063 put options on the stock. This represents an increase of 2,362% compared to the average volume of 165 put options.

Xenon Pharmaceuticals Trading Up 2.7%

XENE stock opened at $42.12 on Thursday. The company’s 50-day moving average price is $42.63 and its 200 day moving average price is $38.55. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.60. The company has a market cap of $3.26 billion, a P/E ratio of -10.83 and a beta of 0.97.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.81) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Analysts Set New Price Targets

XENE has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 14th. Royal Bank Of Canada lifted their price objective on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $54.64.

Read Our Latest Stock Report on Xenon Pharmaceuticals

Insider Activity

In related news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 65,302 shares of company stock valued at $2,924,128 over the last quarter. Insiders own 4.07% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC acquired a new stake in Xenon Pharmaceuticals in the second quarter valued at $25,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth $32,000. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter worth about $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Osaic Holdings Inc. grew its stake in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.